Kerbside

The recommendations provided in this column are taken from various market sources such as brokers, analysts, dealers and investment strategists, etc. These recommendations may not be backed by strong fundamentals. Therefore we advise readers to use their own discretion before investing in these recommendation 

STYLISE YOUR PORTFOLIO 

Shoppers Stop Limited
BSE Code: 532638
CMP: ₹708.35 

Shoppers Stop is India's foremost retailer, renowned for offering a wide array of fashion and beauty brands. There have been several recent developments within the company. Axis Bank has extended its omnichannel shopping segment by partnering with Shoppers Stop to launch the Axis Bank Shoppers Stop Credit Card. This collaboration aims to enhance the shopping experience for customers, offering them exclusive benefits and rewards. Here is the scoop: The company is expanding its retail footprint to reach more customers in various regions. They have opened their first store in Shillong and also strengthened their retail presence in Chennai. Investors to an eye on this buzzing stock. 

RAPID ASCENT IN SIGHT 

Dilip Buildcon Limited
BSE Code: 540047
CMP: ₹446.35 

Gossip mongers! This multibagger operates within the infrastructure development sector, primarily engaged in Engineering Procurement and Construction (EPC) projects. The word on Dalal Street suggests that the company has successfully secured a significant order from Haryana Rail Infrastructure Development Corporation Limited. Valued at ₹1,092.46 crore, this order encompasses the design and construction of a 21.14 km railway line between Prithla and Dhulawat in Haryana. If you don’t want to miss out on this trending stock, then hop on the bandwagon, as Dilip Buildcon is well-positioned for its rapid ascent in the coming times. 

POWER-PACKED WEALTH MANAGER 

Anand Rathi Wealth
BSE Code: 543415
CMP: ₹4,084.75 

Hello gossip enthusiasts! As we enter the Quarterly Results season, one company has shown exceptional performance. Anand Rathi Wealth Limited reported a consolidated net profit of ₹57 crore for Q4FY24, an increase of 33 per cent compared to Q4FY23 and total revenue of ₹197 crore representing an increase of 34 per cent compared to Q4FY23. That’s not all: the board has also recommended a final dividend of ₹9 per share. Interestingly, the board has approved the proposal to buy back shares worth ₹164.65 crore. The stock might see a vertical upswing in the coming times. Keep your eye on this trending stock. 

A PROFIT INJECTOR 

Lupin Limited
BSE Code: 500257
CMP: ₹1,609.20 

Headquartered in Mumbai, this innovation-led transnational pharmaceutical company operates across borders, focusing on research and development to drive its global presence in the healthcare sector. In the U.S. market, Lupin is experiencing mild price erosion, offset by strong growth in its respiratory portfolio, particularly gSpiriva, which is seeing a conversion rate of 30-35 per cent. This is expected to translate into quarterly sales. As price erosion eases and with the launch of complex products and injectables, Lupin anticipates its U.S. sales for FY2026 to reach USD 1 billion, accompanied by an EBITDA margin reaching a five-year high of 21 per cent. Keep an eye on this buzzing stock! 

(Closing price as of April 16, 2024)